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Systemic administration of morphine at low doses has been
shown to elicit acute hyperalgesia in animal models of pain,
i.e., tail flick, Freund’s adjuvant-induced arthritic rats and hot
plate (Kayan et al. 1971; Kayser et al. 1987; Crain and Shen
2001; Galeotti et al. 2006). A specific signaling pathway for
morphine-induced acute thermal hyperalgesia was previously
identified in mouse via mu opioid receptor (lOR) activation
of the phospholipase C beta 3 isoenzyme (PLCb3) and
protein kinase C gamma (PKCc) nociceptive pathway
(Galeotti et al. 2006). N-methyl-D-aspartate (NMDA) recep-
tor activation was also shown to play a role in low dose
morphine-induced acute hyperalgesia suggesting that gluta-
matergic system is implicated in the excitatory response
elicited by low dose opioid administration (Holtman and
Wala 2005; Galeotti et al. 2006). However, the site of action
of morphine and the mechanism of action of lOR activation
by morphine to NMDA receptor are presently unknown as
they relate to acute thermal hyperalgesia. Experiments
performed in cultured neurons demonstrate that lOR opioids
facilitate the activation of NMDA receptors in neurons of
brain regions through activation of protein kinase C (PKC)
(Chen and Huang 1991; Martin et al. 2001). This enzyme
associates physically with NMDA receptor 1 (NR1) subunit
in the post-synaptic density in rat brain, leading to enhance-
ment of synaptic activity (Suen et al. 1998). Post-transla-
tional modification including phosphorylation modulates the
function of NMDA receptors which are phosphorylated on
serines of both NR1 and NR2 subunits and on tyrosine of the
NR2 subunit (Sanchez-Perez and Felipo 2005). Morpholog-
ical evidence showed that the majority of NR1 labeled
dendrites contained lOR labeling in periaqueductal gray
(PAG) (Commons et al. 1999). This region has been
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Abstract
Previous evidence demonstrates that low dose morphine
systemic administration induces acute thermal hyperalgesia in
normal mice through lOR stimulation of the inositol signaling
pathway. We investigated the site of action of morphine and
the mechanism of action of lOR activation by morphine to
NMDA receptor as it relates to acute thermal hyperalgesia.
Our experiments show that acute thermal hyperalgesia is
blocked in periaqueductal gray with the lOR antagonist
CTOP, the NMDA antagonist MK801 and the protein kinase C
inhibitor chelerythrine. Therefore, a site of action of systemi-
cally administered morphine low dose on acute thermal
hyperalgesic response appears to be located at the periaqu-
eductal gray. At this supraspinal site, lOR stimulation by
systemically morphine low dose administration leads to an
increased phosphorylation of specific subunit of NMDA
receptor. Our experiments show that the phosphorylation of
subunit 1 of NMDA receptor parallels the acute thermal
hyperalgesia suggesting a role for this subunit in morphine-
induced hyperalgesia. Protein kinase C appears to be the key
element that links lOR activation by morphine administration
to mice with the recruitment of the NMDA/glutamatergic sys-
tem involved in the thermal hyperalgesic response.
Keywords: hyperalgesia, morphine, mu opioid receptor,
NMDA, phosphorylation, protein kinase C.
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identified as a key component of the pain inhibitory system
since electrical or chemical stimulation of this area sup-
presses nociceptive transmission from the dorsal horn of the
spinal cord (Basbaum and Fields 1984). Importantly, it has
been suggested that opioid effect may extend beyond
inhibition in the PAG. In brain slices, the excitatory action
of NMDA on PAG neurons is potentiated by a lOR agonist
at low nanomolar concentration (Kow et al. 2002). These
results support the hypothesis that the site and the mechanism
of action of morphine low dose, as they relate to acute
thermal hyperalgesia, might reside in PAG. Therefore, we
choose to investigate whether lOR and NMDA antagonist
administration to PAG reverts the thermal hyperalgesic effect
induced by low dose morphine systemic acute administration
to mice. The effect of morphine on phosphorylation of the




Sexually mature male Swiss Webster mice (Morini, S. Polo d’Enza,
Italy), weighing 23–30 g, were used. The animals were fed a
standard laboratory diet and water ad libitum, kept at 23 ± 1C with
a 12-h light/dark cycle and previously habituated to the laboratory
according to Abbot (Abbott et al. 1986). All experiments were
carried out in accordance with the European Community Council
Directive of November 24 1986 for the care and use of laboratory
animals.
Drugs
The following drugs were used: D-Phe–Cys–Tyr–D-Trp–Orn–Thr–
Pen–Thr–NH2 (CTOP), MK801, chelerythrine and morphine HCl
(Sigma Chemicals St Louis, MO, USA). Drugs were administered
in a volume of 0.2 lL per mouse by intracranial infusion, and
10 mL/kg by subcutaneous (s.c.) injection. All drugs were
dissolved in isotonic (NaCl 0.9%) saline solution immediately
before use. Morphine was administered s.c.; CTOP, chelerythrine
and MK801 were administered intra-PAG immediately before
morphine administration; saline was administered both s.c. and
intra-PAG.
Surgery and microinjection
Cannula implantation was performed according to the procedure by
Carvalho-Netto (Carvalho-Netto et al. 2007). Mice were implanted
with 7-mm stainless steel guide cannula (26-gauge) under anesthe-
sia. Stereotaxic coordinates (Paxinos and Franklin 2001) for the
PAG were, respectively, 4.1 mm posterior to bregma, 1.3 mm lateral
to the midline, and 2.2 mm ventral to the skull surface, with the
guide cannula angled 26 to the vertical. A dummy cannula (33-
gauge stainless steel wire) was inserted into each guide-cannula
immediately after each surgery to reduce the incidence of occlusion.
Five to seven days after surgical recovery, solutions were injected
into the PAG by microinjection unit which extended 1.0 mm beyond
the tips of the guide cannula. Each microinjection unit was attached
to a 5-lL Hamilton microsyringe via polyethylene tubing and
administration was controlled by an infusion pump programmed to
deliver a volume at rate of 0.1 lL over a period of 30 s.
Hot plate test
The adopted method was previously described (O’Callaghan and
Holtzman 1975). Mice were placed inside a stainless steel container,
which was set thermostatically at 52.5 ± 0.1C in a precision water-
bath. We used a lower temperature in the hot plate test (52.5C
instead of 54C) to reveal potential, subtle alterations that may occur
in basal thermal nociception. Reaction times (s) were measured with
a stopwatch immediately before morphine or vehicle administration
and 15, 30, and 45 min after; each treatment was blind to the
experimenter. The endpoint for the licking response was the first
paw lick of the front paw. Those mice scoring < 12 and more than
18 s in the pre-test were rejected. All treatments for a same
experiment were performed on the same period of time. Hot plate
test for assaying the effect of different treatments on morphine
hyperalgesia were performed on the same time respectively for
CTOP or MK801 or chelerythrine administration to mice. All
experiments were performed at the same hours (9–13 AM). Mice
were randomly assigned to each group. Dose–response experiments
were done using independent groups.
Effect of treatments on spontaneous motility, inspection
activity and motor coordination
Groups of mice treated with all the used drugs at the highest doses
and saline administered as described in the above experiments, were
submitted to rota-rod (Vaught et al. 1985) and hole-board (Ghelar-
dini et al. 2002) behavioral tests. The apparatus of rota-rod test
consists of a base platform and a rotating rod of 3 cm diameter with
a non-skid surface. The rod was placed at a height of 15 cm from the
base. The rod, 30 cm in length, was divided into five equal sections
by six disks. Thus, up to five mice were tested simultaneously on the
apparatus, with a rod-rotation speed of 16 rpm. The integrity of
motor coordination was assessed on the basis of the number of falls
from the rod in 30 s. Performance time was measured before and 15,
30, and 45 min after administration of the investigated compounds.
The hole board test consisted of a 40 cm square plane with 16 flush-
mounted cylindrical holes (3 cm diameter) distributed four by four
in an equidistant, grid-like manner. Mice were placed on the center
of the board one by one and allowed to move about freely for a
period of 10 min each. Two electric eyes, crossing the plane from
midpoint to midpoint of opposite sides, thus dividing the plane into
four equal quadrants, automatically signaled the movement of the
animal (counts in 5 min) on the surface of the plane (locomotor
activity). Miniature photoelectric cells, in each of the 16 holes,
recorded (counts in 5 min) the exploration of the holes (exploratory
activity) by the mice. Twelve mice per group were tested. The skin
temperature of the mice paws was measured by infrared thermom-
eter (152-IRB thermometer, 2B, Varese, Italy) before and after
administration of the different treatments or saline.
Western blot
Mice were administered with morphine (1 lg/kg), or saline in the
absence or the presence of drugs. Mice were killed at 15, 30, 45 min
and 60 min after morphine or saline administration. Brain was
removed and put immediately in liquid nitrogen. Midbrain was
blocked out and PAG samples were isolated under stereomicroscope
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control (MZ12.5 Leica, Leica, Wetzlar, Germany). Western blot
analysis was performed as previously described in detail (Pan et al.
1995). In summary, membrane homogenates (1 lg/lL protein) from
PAG brain regions of pre-treated or untreated mice were solubilized
in sodium dodecyl sulfate buffer and separated on 10% polyacryl-
amide gels. PAG samples pooled from three brain mice were used
throughout the experiments. Proteins were transferred to nitrocel-
lulose (1.5 h at 190 mA) and the membranes were blocked in
phosphate-buffered saline containing 3% BSA for 1 h before
addition of primary antisera. NMDA NR1 (Upstate, Lake Placid,
NY, USA) and Sc-5274 (b-tubulin) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used as probes at 1 : 1000 dilution. The
same procedure as above was followed to detect NR1 subunit only
when phosphorylated at serine 890 (Cell signalling, Beverly, MA,
USA) or serine 896 (Upstate) except that: blotted nitrocellulose
membranes were blocked for 1 h in freshly prepared 1% BSA-0.1%
Triton X100-TBS (50 mmol/L Tris, 150 mmol/L NaCl pH 7.4) (T-
TBS) and incubated for 4 h in 2 mmol/L MnCl2, 1% BSA, 0.1%
Triton X-100-TBS; T-TBS was used for following incubations. The
specificity for phosphorylated protein of both the above polyclonal
antibodies was previously tested (Brenner et al. 2004; Sanchez-
Perez and Felipo 2005). To further test the specificity of antibodies,
a western blot was cut between two lanes, stripped and one side was
treated with lambda protein phosphatase (Upstate) and the other side
with dilution buffer; the blot was reprobed with anti-NR1 serine 890
or 896 antibodies. All the blottings were visualized using a
chemiluminescence detection system (Super Signal West Fento,
Pierce Biotechnology Inc., Rockford, IL, USA) and quantified with
the Versa Doc 1000 Imaging System (Bio-Rad Laboratories,
Hercules, CA, USA). Protein was determined by the Lowry method
(Lowry et al. 1951) using BSA as standard. PAG samples from each
respective treatment group were processed on the same gel. Tubulin
was used to verify uniform protein loading. The differences
observed as density average values corresponding to saline and
treated mice were expressed as a percentage of saline values. The
relationship between morphine dose and the magnitude of the
phosphorylation density values obtained in PAG sample at 15 min
after morphine administration, was fitted to a dose-effect curve
according to the model:
Intensity of effect ¼ Emax:C
EC50þC ð1Þ
where C is the concentration of the drug, Emax is the maximum
effect and EC50 is the dose which corresponds to 50% of the
maximum effect. The experimental data will be fitted to the dose–
effect mathematical model previously described using Inplot
program (GraphPad InPlot, San Diego CA, USA).
Histology
At the conclusion of the experiments 1% Evans blue dye was
administered to mice according to the microinjection procedure
described above for intra-PAG administration. A post-mortem
histological control of the injection site was performed on cryostat
sections of unfixed brains previously frozen as described for the
western blot methods. The data of any mice were excluded from
statistical analysis if the cannula tip was outside the PAG or if the
region had sustained extensive damage. The brains from mice which
were further submitted to western blot were extracted leaving the
cannula implanted in the brain. The location of cannula inside PAG
was observed under stereomicroscope (Leica MZ12.5, Leica, Solms,
Germany). Only specimens from mice with cannula path inside the
PAG were used for western blot experiments.
Statistical analysis
All experimental results were given as the mean ± SEM. Analysis
of variance ANOVA, followed by Fisher’s protected least significant
difference procedure for post hoc comparison were used to verify
significance between two means of behavioral or immunoblotting
density results. Data were analyzed with the StatView software for
the Macintosh (1992). A significance level (a) < 0.01 was
considered significant.
Results
Effect on hyperalgesia of lOR receptor and NMDA
antagonist
The thermal hypernociception induced by morphine was
prevented by pre-treatment with CTOP at 80 ng (Fig. 1).
Lower doses were ineffective. Baseline level were
re-established for all pre-treatments at 45 min after morphine
administration. CTOP, when administered alone, did not
modify the licking latency of mice in comparison with saline
administered animals (Fig. 1). The administration of site-
specific NMDA receptor antagonist MK801 to PAG pro-
duced a dose-dependent inhibition of the hyperalgesic effect
induced by 1 lg/kg s.c. morphine administration to mice
Fig. 1 Prevention of morphine induced hyperalgesia by PAG pre-
treatment with CTOP at different doses. The licking latency values
represented in figure were measured before (0), 15, 30, and 45 min
after s.c. morphine administration (1 lg/kg) in presence or absence of
CTOP infused to PAG at increasing doses. Vertical bars represent
SEM; *and D = a < 0.01 significant difference in comparison respec-
tively with 1 lg/kg morphine or s.c. saline induced licking latency value
measured at the same time. Each value represents the mean ± SEM
of the licking latency values. The number of mice used for each
treatment is reported on vertical bars at 0 time. MF = morphine.
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(Fig. 2). The treatment with MK801 at 0.8 ng completely
reversed to basal value morphine-induced hyperalgesia.
MK801, when administered alone, did not modify the
licking latency of mice in comparison with saline adminis-
tered animals (Fig. 2). Baseline level were re-established for
all pre-treatments at 45 min after morphine administration.
Thermal hyperalgesic effect elicited by 1 lg/kg s.c. mor-
phine administration to mice was unmodified by intra-PAG
saline injection pre-treatment (Fig. 3).
Effect of PKC inhibitor on hyperalgesia
The PKC inhibitor chelerythrine, administered to PAG at
different doses, completely reversed the 1 lg/kg morphine
hyperalgesic effect at the higher dose (Fig. 4). A return to
basal level was observed at 45 min after morphine admin-
istration for all chelerythrine doses. Chelerythrine, when
administered alone, did not modify the licking latency of
mice in comparison with saline administered animals
(Fig. 4).
Effect of treatments on mouse motor coordination and
spontaneous motility
Mice pre-treated with s.c. morphine, intra-PAG CTOP,
MK801 and chelerythrine at the highest doses used in
experiments previously described, were evaluated for motor
coordination by use of the rotarod test and for spontaneous
motility and inspection activity by use of the hole board test.
The spontaneous motility as well as inspection activity of
mice were unmodified by treatment with drugs in comparison
with saline administered group (Fig. 5a). The number of falls
from the rotating road evaluated before and 15, 30, and
45 min after the beginning of the rotarod test, showed the
lack of any impairment in motor coordination of mice pre-
treated with the above drugs in comparison with saline group
Fig. 2 Prevention of morphine-induced hyperalgesia by PAG pre-
treatment with MK801 at different doses- The licking latency values
represented in figureweremeasured before (0), 15, 30, and 45 min after
intra-PAG MK801 infusion or s.c. morphine administration (1 lg/kg) in
presence or absence of MK801 at increasing doses. Vertical bars rep-
resent SEM; * and D = a < 0.01 significant difference in comparison
respectively with 1 lg/kg morphine or s.c. saline induced licking latency
value measured at the same time. Each value represents the
mean ± SEM of the licking latency values. The number of mice used for
each treatment is reported on vertical bars at 0 time. MF = morphine.
Fig. 3 Morphine hyperalgesic effect after intra-PAG saline adminis-
tration- The licking latency values represented in figure were mea-
sured before (0), 15, 30, and 45 min after s.c. morphine administration
(1 lg/kg) in presence or absence of intra-PAG saline administration.
Vertical bars represent SEM value measured at the same time. Each
value represents the mean + SEM of the licking latency values;
* = a < 0.01 significant difference in comparison with s.c. saline in-
duced licking latency value measured at the same time. The number of
mice used for each treatment is reported on vertical bars at 0 time.
MF = morphine.
Fig. 4 Prevention of morphine-induced hyperalgesia by PAG pre-
treatment with chelerythrine at different doses. The licking latency
values represented in figure were measured before 0, 15, 30, and
45 min after intra-PAG chelerythrine infusion or s.c. morphine
administration (1 lg/kg) in presence or absence of chelerythrine at
increasing doses. Vertical bars represent SEM; * and D = a < 0.01
significant difference in comparison respectively with 1 lg/kg mor-
phine or saline induced licking latency value measured at the same
time. Each value represents the mean + SEM of the licking latency
values. The number of mice used for each treatment is reported on
vertical bars at 0 time. MF = 1 lg/kg morphine.
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(Fig. 5b). These behavioral tests show that drugs used in hot
plate test experiment do not induce any significant change in
motor coordination and spontaneous motility. The skin
temperature of the mice paws remained unchanged after
administration of the different pre-treatments or after surgery
(data not shown) showing that different treatments or surgery
do not induce any significant change.
Immunoblotting
Immunoblotting analysis revealed a significant increase of
S890 NR1 phosphorylation with respect to basal value in
PAG after 1 lg/kg morphine s.c. administration at 15, 30,
and 45 min; 60 min after morphine administration the
density value was not significantly different (Fig. 6a and
b). NR1 content was not significantly modified by morphine
administration (Fig. 6a). CTOP and chelerythrine adminis-
tered to PAG prior to morphine blocked the S890 NR1phos-
phorylation increase (Fig. 6a and b). Mice pre-treated with
intra-PAG CTOP (80 ng) or chelerythrine (5 ng) administra-
tion were submitted to western blot analysis as previously
described. No increase in phosphorylation on S890 NR1
could be detected in PAG from mice administered with these
treatments with respect to basal value (Fig. 7a and b).
NMDA NR1 content was not afflicted by CTOP or
chelerythrine intra-PAG administration (Fig. 7a). Morphine
dose dependently (0.01–7000 lg/kg) increased the phosp-
orylation of S890 NR1 in PAG samples; the maximum
increase was reached at the 1 lg/kg dose administration to
mice and further increase was not obtained at the higher
doses (Fig. 8a and b). NR1 content was not afflicted by
morphine administration (Fig. 8a). No increase of phosphor-
ylation on serine 896 NR1 could be detected in PAG from
mice administered with morphine (data not shown). Immu-
noblots were re-probed for b-tubulin which served as a
loading control; no % significant density difference was
revealed for this protein between lanes of the same immu-
noblotting. The band for S890 NR1 was lost when the
proteins on the blot were dephosphorylated by exposure to
lamba phosphatases (Fig. 9).
Histology
Histology confirmed that 96% mice used in the experiments
had cannula placement within the PAG (Fig. 10).
Discussion
Role of opioid and glutamatergic receptors in the mouse
PAG in the morphine-induced hyperalgesic response
In our experiments, exposure of PAG neurons to selective
lOR antagonist CTOP at the higher dose completely
reversed the morphine low dose-induced acute hyperalgesic
response and this effect was dose-dependent. Low dose
morphine-induced hyperalgesia appears to be lOR mediated
at this supraspinal site even if the lOR subtype implicated in
the hyperalgesic response is presently unknown (Cadet et al.
2003). PAG contributes to a different range of behaviors
which are related to functional subdivisions in this area. The
hyperalgesic response induced by morphine occurred as a
result of activation of lOR receptor in dorsal lateral PAG, an
area evocating flight reactions which usually follow an
excitatory stimulus (Morgan et al. 1998). Since lesioning/
blocking supraspinal regions reduces the hyperalgesia
induced by formalin, mustard oil or spinal nerve injury, it
further supports the participation of PAG in the execution
and facilitation of spinal nociceptive reflexes (Wiertelak
et al. 1994; Mansikka et al. 1996; Wei et al. 1998; Urban
and Gebhart 1999). There is also considerable evidence that
the hyperalgesia or allodynia associated with nerve injury or
inflammation depends on activation of NMDA receptors. For
example, the administration of NMDA receptor antagonists,
such as MK801, ketamine or memantine strongly reduces
hyperalgesia or allodynia in animals, including man (Carlton
and Hargett 1995; Eisenberg et al. 1998; Wei and Pertovaara
1999; Ozyalcin et al. 2004; Gottrup et al. 2006). Evidence
for NMDA receptor activation in rodent brain during the
hyperalgesic response to low dose morphine systemic
administration was recently demonstrated (Holtman and
Fig. 5 Lack of effect by different treatment morphine (1 lg/kg), CTOP
(80 ng), MK801 (0.8 ng) and chelerythrine (5 ng) administered to mice
at higher effective doses on spontaneous motility/inspection activity
(a) and motor coordination (b). Number of falls in 30 s measured in
treated mice was compared with s.c. saline values measured at the
same time (b). Vertical lines represent SEM.
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Wala 2005; Galeotti et al. 2006). When NMDA receptor in
PAG was blocked by the selective antagonist MK801 at
different doses, the activation of lOR by morphine low dose
could not induce the hyperalgesic response in presence of the
higher MK801 dose showing that opioid and glutamatergic
receptors in PAG are both implicated in inducing the
hyperalgesic response elicited by systemic morphine admin-
istration. At the same time, acute thermal hyperalgesic
response induced by morphine low dose administration to
mice is lacking in presence of the selective PKC inhibitor
chelerythrine administered intra-PAG showing that the
hyperalgesic effect is mediated by this kinase at PAG level.
In vitro, lOR stimulation has been shown to start the
activation of NMDA receptors by increasing intracellular
PKC activity in trigeminal neurons (Chen and Huang 1991)
as well as translocation of the cytosolic PKCc to the plasma
membrane leading to phosphorylation of the NMDA recep-
tors implicated in pain promotion (Suen et al. 1998). It
would appear that low dose morphine lOR coupling might
initiate PKC translocation and activation which causes a
removal of Mg++ blockade of NMDA receptor (Chen and
Huang 1992). With this blockade removed, even small
amounts of glutamate ligands, which could be basally
released from pre-synaptic terminals, may activate the
NMDA receptor and allow localized Ca++ channels to open
triggering the excitatory response.
NMDA receptor phosphorylation in PAG neurons in
morphine induced hyperalgesic response
NMDA receptors are phosphorylated and dephosphorylated
by a variety of kinases that regulate NMDA receptor
function. Different reports have shown that phosphorylation
Fig. 6 Morphine administration (1 lg/kg, s.c.) significantly increases
phosphorylation on NR1 S890 in PAG sample at 15, 30, and 45 min
after morphine administration. Phosphorylation returns to basal level
at 60 min after morphine administration. A representative immunoblot
is shown with b-tubulin as loading control (a). Morphine (1 lg/kg, s.c.)
administered in presence of selective lOR antagonist CTOP (80 ng,
intra-PAG) or chelerythrine (5 ng, intra-PAG) failed to increase NR1
S890 phosphorylation (a). Anti-NR1 detection is reported in (a) using
the membrane revealed for S890 phosphorylation previously stripped
and re-incubated with anti-NR1 antibody. The mean + SEM of phos-
phorylation density values obtained in PAG from five different exper-
iments are reported in (b). Values are expressed as percentage of
density obtained in s.c. saline-treated mice; * indicates difference at
a < 0.01 significance level in comparison with control value.
MF = morphine.
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of the NMDA NR1 subunit is associated with noxious
stimulation demonstrated by capsaicin, carrageenan and
formalin injection to rodents (Zou et al. 2002; Caudle et al.
2005; Kim et al. 2006). Particularly, PKCc effects the NR1
subunit phosphorylation at serine 890 as well as cyclic AMP-
dependent PKCa mediates phosphorylation at serine 896
(Sanchez-Perez and Felipo 2005). In our experiments, the
morphine-induced hyperalgesic effect is accompanied by an
increase in phosphorylation of serine 890 aminoacidic
residue in the NR1 subunit of the NMDA receptor in PAG
whereas no phosphorylation increase could be detected on
serine 896 in the same experimental conditions. NR1 subunit
appeared to be higher phosphorylated on serine 890 with
respect to basal value in PAG samples from mice killed at 15
and 30 min after morphine administration. At these times, a
thermal hyperalgesic response was observable. Phosphory-
lation increase on NR1 subunit S890 was still observable at
45 min after morphine administration when the hyperalgesic
response was reversed to basal level. A return to basal
phosphorylation level could be observed at 60 min after
morphine administration and, at that time, no hyperalgesic
effect could be revealed. Our experiments show that the
phosphorylation of subunit 1 of NMDA receptor and the
acute thermal hyperalgesia are temporally related even if
there is an inconstancy in the time course of phosphorylation
of NR1 S890 by morphine and morphine-induced hyperal-
gesia. The later return to basal value of NMDA receptor
phosphorylation induced by activation of kinases was
previously observed. Phosphorylation increase of NR1 by
PKC on serine 890 in hippocampus lasted for the first 3 h
following the termination of drug induced status epilepticus
in rat before returning to basal values (Niimura et al. 2005).
Phoshorylation on serine 890 in mouse PAG appeared to be
Fig. 7 CTOP (80 ng) and chelerythrine (5 ng) intra-PAG administra-
tion to mice does not increase NR1 S890 phosphorylation in PAG
sample at 15, 30, 45 and 60 min after administration (a). Morphine s.c.
administration (1 lg/kg), used as positive control, significantly
increases phosphorylation on NR1 S890 at 15 and 30 min after
administration. A representative immunoblot is shown with b-tubulin as
loading control (a). Anti-NR1 detection is reported in (a) using the
membrane revealed for S890 phosphorylation previously stripped and
re-incubated with anti-NR1 antibody. The mean + SEM of phosphor-
ylation density values obtained in PAG from five different experiments
are reported in (b). Values are expressed as percentage of density
obtained in saline-treated mice; * indicates difference at a < 0.01
significance level in comparison with control value (0 time).
MF = morphine.
Fig. 8 Morphine administration at different doses (0.01–7000 lg/kg)
dose dependently increase the phosphorylation of NR1 S890 in PAG
sample (a). The higher density values were obtained at 1–7000 lg/kg
dose administration to mice (a and b); * indicates difference at
a < 0.01 significance level in comparison with saline value. A repre-
sentative immunoblotting is shown with b-tubulin as loading control (a).
NR1 content is shown in the same membrane previously stripped and
re-incubated with anti-NR1 antibody (a). The fitting of phosphorylation
density with respect to morphine concentration to the mathematical
eqn (1) is reported in (b). A value of 192 ± 12% and 0.08 ± 0.04 lg
were obtained respectively for Emax and EC50 (b).
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morphine dose-dependent and the maximum phosphorylation
effect was obtained at 1 lg/kg dose administration to mice.
Higher morphine doses failed to further increase phoshory-
lation level confirming that phosphorylation increase on
serine 890 is saturated at hyperalgesic doses. The increase in
phosphorylation of NR1 S890 in PAG induced by morphine
systemic administration to mice was blocked in presence of a
selective lOR antagonist injected directly to PAG demon-
strating that NR1 receptor alteration is triggered by lOR
ligand in this brain region. Morphological evidence showed
that the majority of NR1 labeled dendrites contained lOR
labeling in PAG (Commons et al. 1999). Co-immunoprecip-
itation studies revealed that NR1 is physically associated
with functional active PKC; particularly, PKCc is associated
physically with NR1 subunit in the rat brain suggesting that
these receptors may be directly phosphorylated by the kinase
(Suen et al. 1998). In our experiments, the inhibition of PKC
reverts to basal value the NR1 S890 phosphorylation increase
in PAG induced by morphine hyperalgesic dose confirming
that NR1 phosphorylation in this area is induced by PKC
activation.
Conclusions
Taken the data as a whole, our findings show that a site of
action of morphine low dose on acute thermal hyperalgesic
response is located at the PAG. At this supraspinal site, lOR
stimulation by systemically morphine low dose administra-
tion leads to an increased phosphorylation of specific subunit
of NMDA receptor suggesting a role for the NR1 subunit of
the NMDA receptor in morphine-induced hyperalgesia.
These data strongly imply a molecular interaction, at
supraspinal level, between NMDA and opioid receptors in
morphine-induced acute nociception. PKC appears to be the
key element that links lOR activation by morphine low dose
with the recruitment of the NMDA/glutamatergic system in
PAG. Our finding agrees with previous evidence of active
pronociceptive processes initiated by opioid administration
(Mao 2002). Preclinical studies have shown that systemic
opioid administration in rodents can lead to an abnormal pain
sensitivity as shown by a long-lasting reduction of baseline
nociceptive threshold (Laulin et al. 1998); opioid-induced
pain sensitivity can develop rapidly after an acute systemic
opioid exposure as observed in human volunteers (Guignard
et al. 2000; Angst et al. 2003). The central glutaminergic
system plays a pivotal role in these neural mechanisms and
NMDA receptor has been shown to be critical in the cellular
mechanisms of opioid-induced pain sensitivity (Chen and
Huang 1991; Mao et al. 1995). Hyperalgesia is observed both
in animal model after administration of low morphine dose or
as a delayed response seen subsequent to the analgesic
response produced by central or systemic administration of
opioid agonists to humans (Celerier et al. 2000; Mao 2002;
Richebe et al. 2005). These paradoxical effects were usually
ascribed to progressive reduction of opioid effects, occurring
over a period of weeks, with repeated drug administration as in
tolerance or following a single opiate administration as in
short-term tolerance. Our findings provides some preclinical
evidence that tolerance – especially short-term tolerance –
may be not mainly due to a decrease in opioid effectiveness,
but might result from the activation of nociceptive facilitatory
systems at later times after morphine analgesic dose admin-
istration when the opioid concentration is expected to be as
low as morphine concentration at supraspinal site after low
dose administration.
Fig. 10 Schematic representation of microinfusion site distribution
within (filled circle) and outside (black circle) PAG area of brain mouse.
The number of the filled circles is less than the total number of mice
because of overlaps. The distance from bregma is represented on
right side.
Fig. 9 Western blot of mice PAG sample revealed for NR1 S890
phosphorylation in the presence (right side) or the absence (left) of
k-posphatase. b-tubulin was used as loading control.
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